Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Henry Schein Picks up Another Dental Distribution Service

by | Sep 1, 2016 8:17 pm | Other Services

In late August 2016, Henry Schein, Inc. (NASDAQ: HSIC) announced its seventh dental acquisition since 2014. The acquisition of Marrodent gave the global dental products giant a presence in Poland, where Marrodent distributes dental equipment and dental laboratory supplies. With this addition, Henry Schein’s dental business now has operations or affiliates in 27 countries. In 2014, Henry Schein purchased five European dental companies from Arseus NV (EBR: RCUS), as well as New Jersey-based Lincoln Dental Supply, a supplier of dental products and equipment, and France-based Sirona Direct, the dental distribution business of Sirona Dental Systems Inc. (NASDAQ: SIRO). In 2015, the... Read More »

Big Pharma Pays Big for Biotech Pipelines

by | Sep 1, 2016 6:43 pm | Biotechnology, Pharmaceuticals

The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is that these acquirers are now targeting early-stage and even pre-clinical drug candidates, to boost their own production pipelines, but as a way to stymie the competition, too. Pharmaceutical mergers and acquisitions hit a peak in 2014, with 188 deals (up 25% year-over-year) and $213.3 billion in spending (up 220%... Read More »

Microbot Medical Merges with StemCells

by | Aug 30, 2016 6:01 pm | Biotechnology, Medical Devices

Microbot Medical Ltd., an Israel-based medical device company that specializes in the research, design, development and commercialization of micro-robotics-assisted medical technologies, has merged with StemCells Inc. (NASDAQ: STEM), a biotech firm that engages in the research, development, and commercialization of stem cell-based therapeutics for the treatment of central nervous system diseases. For StemCells, this merger is a strategic alternative to its failed Phase 2 clinical study of human neural stem cells in chronic spinal cord injuries. The combined company will pursue the development of robotics-based medical devices for the treatment of cerebrospinal fluid and gastrointestinal... Read More »

Busy Day for Bacterial Infection Drugs

by | Aug 26, 2016 8:40 am | Biotechnology, Pharmaceuticals

On August 23rd, two separate deals occurred involving licenses to drug candidates for the treatment of serious infections. Productos Científicos S.A. de C.V. (PC), a leading privately-held Mexican pharmaceutical company, purchased a license to Taigexyn® in Latin America from privately-held TaiGen Biotechnology Company Limited. Taigexyn® (nemonoxacin) is a novel antibiotic for the treatment of bacterial infections, including those caused by drug resistant bacteria, which has proven its efficacy in Phase I, II and III clinical studies. According to IMS Health, Latin-America’s pharmaceutical market is projected to grow 9-12% from 2016-2020, faster than the projected 3-6% in more developed... Read More »

BioClinica Changes Hands as CRO Market Heats Up

by | Aug 25, 2016 8:25 am | Other Services, Private Equity

The market for contract research organizations (CROs) is hot in 2016. Fourteen deals have been announced so far this year, compared with five in all of 2015, 11 in 2014 and eight in 2013. The latest deal was announced on August 22, as JLL Partners and Water Street Healthcare Partners exited their investment in BioClinica, Inc. and the UK-based private equity firm Cinven stepped in, for an undisclosed price. The original investment for the global clinical trial management company, then trading under the NASDAQ ticker symbol BIOC, was announced on January 30, 2013, for $123 million (1.6x revenue and 11.8x EBITDA). That deal included the acquisition of medical imaging company CoreLab... Read More »

Pfizer Buys Medivation and More

by | Aug 24, 2016 8:15 am | Pharmaceuticals

Forget those early- to mid-stage clinical candidates. Pfizer Inc. (NYSE: PFE) jumped the line with its $13.5 billion deal for oncology drug maker Medivation Inc. (NASDAQ: MDVN). The target’s primary product is XTANDI® (enzalutamide), an androgen receptor inhibitor, the leading novel hormone therapy for the treatment of prostate cancer. Pfizer will pay $81.50 per share in existing cash, a 21% premium to Medivation’s closing stock price on Friday, August 19, 2016. This deal ends months of bidding for Medivation, which began in April with Sanofi SA’s $52.50 per share (about $9 billion) offer. Medivation turned down the overture, and Sanofi eventually raised its bid to $58.50... Read More »

Jefferson Health Adds Another Health System

by | Aug 23, 2016 6:27 pm | Hospitals

Jefferson Health System, the not-for-profit system that is part of Thomas Jefferson University Hospitals, signed a definitive agreement to integrate with Kennedy Health, a three-hospital system (607 beds) in southern New Jersey. The transaction is expected to be completed following New Jersey’s Community Health Care Assets Protection Act review process. The boards of Kennedy and Jefferson unanimously approved the agreement, which extends the shared governance model that was established with the integration of Abington Health (January 2015) and Aria Health (July 2016). Like Jefferson, Abington and Aria, Kennedy will have equal representation on the expanded Jefferson board. With the... Read More »

Specialty Pharmacy Extends Reach in Healthcare

by | Aug 19, 2016 6:46 pm | Behavioral Health Care, eHealth, Other Services, Private Equity

Genoa, a QoL Healthcare Company, a leading behavioral health specialty pharmacy company, has acquired the behavioral health and residential care services division of Advanced Care Pharmacy Services, including 13 of its pharmacies in Michigan. Genoa is a portfolio company of Advent International. In November 2015, Genoa acquired 1DocWay, the nation’s largest outpatient telepsychiatry provider, for an undisclosed price. Advanced Care Pharmacy Services is a privately-held Alabama-based provider of specialized pharmacy services for a variety of care settings. Genoa’s purchase, which did not disclose a price, increases its number of Michigan-based pharmacies to 24, and 325 nationally.... Read More »